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remains debatable. As many as 300 (or 33.4%) out 
of 897 haemodialysis (HD) patients of our center 
were positive for HBV-antibodies. 'Isolated' anti- 
HBc (HBsAg, HBsAb were not found) were detected 
in 194 patients (64.7%), while HBsAb was found only 
in 31 patients (10.3%), and HBsAb together with 
HBcAb were found in 75 patients (25%). 
Methods: Twenty seven HD patients (age 44.3±2.6; 
15 males, 12 females)with 'isolated' HBcAb were 
randomly assigned for study a new approaches of 
immunization against HBV infection. Schedule of 
vaccination of A.Mclntyre et al. (1992) was adapted 
for HD patients. All patients were immunized by 
40 mcg of HBV vaccine 'Combiotech' (Russia). Blood 
samples were obtained for quantitative determina- 
tion of HBsAb in 1 month after the first vaccination. 
If the HBsAb titers were higher than 50mlU/ml, 
the immunization was terminated. In this case 
'isolated' HBcAb could be considered as a sign of 
past HBV infection. In patients with lower level of 
HBsAb vaccination was continued using a 'standard' 
schedule for HD patients (1-2-6 months). 
Results: The HBsAb titers a month after the end of 
immunization are shown in Table 1. 
Tab[e 1. Resu[ts of vaccination of patients with 'iso[ated' HBcAb 
and with HBsAb <50mlU/m[ one month after the first vaccine 
injection. 
HBsAb HBsAb (mlU/m[) at end of vaccination 
(mlU/m[) 1 mo after first injection 
< 10 10-99 100-499 < 500 Tota[ 
<10 1 3 2 - 6 
10-50 - 3 3 2 8 
Total 1 6 5 2 14 
Conclusion: Nearly half of the patients with the 
'isolated' HBcAb responded by a protective titer 
only after complete course of immunization. Pos- 
sibly the detection of this marker had pseudo- 
positive character. Thus, the suggested vaccination 
scheme allows one to increase its efficiency in HD 
patients with 'isolated' HBcAb. 
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Background E Methods: Vaccination efficacy 
against the HBV infection was studied in 175 
haemodialysis (HD) patients (96 males, 79 fe- 
males, 49±0.8 years old) who had no signs of 
HBV infection (no HBsAg, HBsAb and HBcAb). The 
duration of the HD therapy prior to immuniza- 
tion was 10.2±0.7 months. Chronic renal failure 
mainly resulted from chronic glomerulonephdtis in 
33.1% of patients, diabetic nephropathy (19.4%) 
and chronic pyelonephdtis (16.6%). Patients were 
immunized with "Engerix B" (GlaxoSmithKline) or 
"Combiotech" (Russia) by injecting 40 mcg of vac- 
cine at 0th, 1st, 2nd and 6th month. 
Results: The results were monitored for 36 months 
after the end of vaccination. In one month the 
HBsAb titers of 10 mlU/ml or higher were found in 
147 patients (84%). The dynamics of the level of the 
HBsAb titers during the next 36 months is shown in 
Table 1. The number of patients with the HBsAb 
titres less than 10mlU/ml divided by the number 
of patients having certain HBsAb level at the end 
of immunization is presented. 
Tabte 1. Number of patients with HBsAb < 10 mlU/m[ at different 
stages of fottow-up at different revers of post-immunization 
titres 
HBsAb 18mo 24mo 30mo 36mo 
(mlUlm[) (n =97) (n =78) (n = =69) (n =40) 
n % n % n % n % 
10-99 10/18 56 13/15 87 13/15 87 13/13 100 
100-499 4/25 16 5/16 31 6/13 46 8/9 89 
500 0/54 0 1/47 2 3/41 7 7/18 39 
Conclusion: The rate of decreasing of protective 
antibody titers in HD patients depended on re- 
sponse intensity at the end of vaccination. It may 
be the rationale for revaccination in HD patients. 
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Background: EBV related PTLD has been recog- 
nized as a serious complication of immunosuppres- 
sion in patients undergoing bone marrow trans- 
plants, and solid organ transplants. The presence of 
EBV related PTLD outside of the transplant world, 
has been reported less frequently. We report a 
case of biopsy confirmed polyclonal EBV PTLD in a 
patient with Crohns disease, and successful treat- 
ment with gancidovir. 
Case: A 17 yr female with a known history of 
Crohns disease presented in August with symptoms 
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of fever, weight toss, swollen neck glands, sore 
throat, and decreased appetite. A workup at the 
time confirmed a diagnosis of EBV mononudeo[o- 
sis syndrome, confirmed by serology. The patient 
had been on Imuran. A decision was made at the 
time to discontinue her Imuran therapy in view 
of her significant symptoms with resolution of her 
symptoms. By September a decision to restart 
imuran was made. The patient presented next in 
November of the same year, with a 5 week history 
of fever, weight toss, abdominal pain, and toss 
of appetite. W/up included CT chest, abdomen 
and pelvis, and a colonoscopy. CT chest showed 
micronodu[arity in both tung fields, and lesions 
seen in spleen and liver. Co[onoscopy identified 
ulcerations at the [eve[ of the cecum, multiple 
biopsies were taken: mild colitis at the [eve[ of the 
sigmoid colon, at the [eve[ of the cecum atypical 
[ymphocytes admixed with histiocytes and plasma 
celts, and positive on EBV staining. A liver biopsy 
of one of the lesions showed extensive necrosis, 
atypical [ymphocytes, histiocytes, very occasional 
plasma celts, and eosinophi[s, again EBV stains 
were positive, CD68+ and CD3+ T celts. A EBV PCR 
semiquantitative at the time showed 100-1000 per 
million PBMC. Given the po[yc[ona[ nature of the 
PTLD, and incomplete response to towering im- 
munosuppression in the past, a decision was made 
to start ganciclovir at a dose of 200 mg q12h IV for 
7 days. The patients symptoms improved within a 
week, and f/up biopsy of the cecum in December 
showed florid granulation tissue with inflammatory 
exudates small T ce[[s(CD3 positive), but negative 
on EBV stains. The f/up EBV PCR semiquantitative 
showed 10-100 per million PBMC. 
Conclusions: There have been a few reports of 
EBV related PTLD in patients with Crohns Dis- 
ease.(Tab[e 1) In most cases EBV re[. PTLD resolves 
with towering of immunosuppression, but in select 
cases of po[yc[ona[ PTLD, gancic[ovir therapy can 
be an effective treatment option. 
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Background: Invasive asper~illosis is a severe com- 
plication occurring most commonly in neutropenic 
patients with leukemia or bone marrow transplan- 
tation. We describe the course and the antifunga[ 
treatment of in a non-neutropenic patient with 
generalized aspergillosis. 
Case report: A 63-year old woman with renal 
Wegener's granulomatosis developed fever refrac- 
tory to imipenem, vancomycin and fluconazo[e 
after 3-months treatment with cydophospamid 
(1 g every 4 weeks) and predniso[on 0.5-1 mg/kg. 
A CT scan showed abscesses in the thyroid gland 
besides unspecific infiltrates within both lungs. The 
aspiration of a thyroid abscess yielded the growth 
of Aspergillus flavus. The patient did not respond to 
the treatment of voriconazo[e and was transferred 
to our hospital 
The patient was in a reduced genera[ condition 
with a normal neutrophi[ count, a slightly elevated 
serum creatinine and no signs of active Wegener's 
granu[omatosis. A MRT of the skull revealed a 
lesion in the brain compatible with cerebra[ as- 
pergillosis. The CT scan of the tung was suggestive 
for pu[mona[ aspergillosis. A combination therapy 
with amphotericin B (1 mg/kg/24 h) plus caspofun- 
gin 50mg/d was started. At[ immunosuppressive 
treatment was stopped. The patient's condition im- 
proved. However she complained of increasing nau- 
sea and absolute toss of appetite. Thus parentera[ 
nutrition was started. Eight weeks after initiation 
of therapy, the cerebra[ lesion was slightly smatter, 
the pu[mona[ lesions were increasing. Addition- 
ally, subcutaneaous nodules and abcesses in the 
myocardium were detected. Artificial respiration 
had to be started because of respiratory failure. 
A further aspiration of the stilt existing thyroid 
abscesses revealed masses of hypha[ elements but 
no growth in the funga[ culture. Panfunga[ PCR 
hinted the presence of an ascomycete other than 
Asper~illus. The antifunga[ therapy was switched 
to amphotericin B plus voriconazo[e, then to oral 
posaconazo[e. The patient improved. Because of 
increasing cho[estasis, posaconazo[e was stopped 
after 3 weeks. The patient died 14 days tater. 
The autopsy revealed suppurative cho[angitis, the 
cultures are still pending. 
Discussion: Generalized aspergillosis is consid- 
ered a disease in neutropenic patients. However, 
in severely immunosuppressed patients mu[tifoca[ 
fungal disease caused by more than one fungal 
species may develop. 
